This debate pack has been compiled ahead of the debate on the availability of cancer drugs, to be held in Westminster Hall on Tuesday 20 October 2015 at 9.30am. The member in charge of the debate is Jim Shannon MP.
Availability of cancer drugs (491 KB , PDF)
This debate pack has been compiled in preparation for the debate. It contains a brief summary of the issue and a selection of relevant media articles, press releases and Parliamentary Questions pertinent to the debate.
There are a number of different steps a drug must go through to be authorised for use by the NHS and the process for the assessment of drugs’ clinical effectiveness and value for money varies in different parts of the UK. England is the only part of the UK that has a specific fund to pay for cancer drugs that would not ordinarily be provided by the NHS due to their high cost. Cancer drugs may also be funded by the Scottish Government’s New Medicines Fund, set up last year to expand and replace the Rare Conditions Medicines Fund, which supports health boards to fund the cost of orphan, ultra-orphan and end-of-life drugs for patients.
Before a medicine can be sold or prescribed in the UK it must receive a marketing authorisation (previously known as a product license) either from the European Medicines Agency or from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Doctors can prescribe any medicine that has received a marketing authorisation although the NHS has policies, both at the local and national level, which specify what will and will not be funded.
Patients in England and Wales have the right to cancer drugs and treatments that have been recommended by the National Institute for Health and Care Excellence (NICE). NICE technology appraisals consider the clinical and cost-effectiveness of new healthcare interventions and the NHS in England and Wales is legally required to fund those treatments recommended by NICE in its technology appraisal guidance. The Department of Health, Social Services and Public Safety (HPSS) in Northern Ireland also uses guidance issued by NICE in determining its funding decisions.
There is a different system for making decisions on the funding of drugs in Scotland, where the Scottish Medicines Consortium (SMC) also reviews all new drugs on the basis of their clinical and cost-effectiveness. NHS boards in Scotland are expected to follow the advice of the SMC.
Further information about how each part of the UK decides which drugs to fund can be found on the Cancer Research UK website.
Debate packs are intended to provide a summary or overview of the issues being debated and identify any relevant briefings including press and parliamentary material. A more detailed briefing may be prepared for a Member on request to the Library.
Availability of cancer drugs (491 KB , PDF)
A debate has been scheduled in Westminster Hall for 3pm on 23 January on innovation in the field of rare retinal disease. The subject for the debate has been chosen by the Backbench Business Committee, and the debate will be opened by Jim Shannon MP.
A debate has been scheduled in the Commons Chamber on 20 January on the impact of food and diet on obesity. The subject for this debate has been chosen by the Backbench Business Committee, and the debate will be opened by Dr Simon Opher MP.
A Westminster Hall debate on the provision of auditory verbal therapy is scheduled for Tuesday 21 January 2025 at 9:30am. The debate will be led by Mrs Sharon Hodgson MP.
